Robeco Institutional Asset Management B.V. Has $26.53 Million Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Robeco Institutional Asset Management B.V. lifted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 6.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 213,709 shares of the specialty pharmaceutical company's stock after acquiring an additional 12,405 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.35% of Jazz Pharmaceuticals worth $26,532,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Focus Partners Wealth bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $551,000. CX Institutional acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at about $4,316,000. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock valued at $542,000 after buying an additional 1,223 shares during the period. Atria Investments Inc lifted its stake in shares of Jazz Pharmaceuticals by 19.5% in the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock valued at $336,000 after buying an additional 445 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Jazz Pharmaceuticals by 15.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock worth $75,801,000 after buying an additional 83,807 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 9th. The shares were acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the transaction, the director directly owned 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the sale, the chief executive officer directly owned 439,307 shares in the company, valued at approximately $51,113,369.45. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. Insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several recent research reports. Truist Financial upped their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Morgan Stanley reduced their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Finally, Royal Bank Of Canada lowered their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $3.32 on Tuesday, hitting $109.44. The stock had a trading volume of 754,237 shares, compared to its average volume of 827,332. The firm's 50 day moving average price is $108.87 and its 200-day moving average price is $119.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a market capitalization of $6.62 billion, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 4.58 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's revenue for the quarter was down .5% on a year-over-year basis. During the same period in the prior year, the business earned $2.68 earnings per share. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.